PPNDS is an agonist, not an antagonist, for the ATP receptor of Paramecium.
Paramecium represents a simple, eukaryotic model system to study the cellular effects of some neuroactive drugs. They respond to the agonist beta,gamma-methylene ATP with a transient depolarizing receptor potential, Ca(2+)-based action potentials and repetitive bouts of forward and backward swimming called 'avoiding reactions' (AR). In vivo [(32)P]ATP binding assays showed saturable [(32)P]ATP binding with an apparent K(d) of approximately 23 nmol l(-1). Prolonged (15 min) exposure to 25 micro mol l(-1) beta,gamma-methylene ATP caused behavioral adaptation and losses of AR, ATP receptor potentials and [(32)P]ATP binding. While screening various ATP receptor inhibitors, we found that the P2X1 'antagonist' pyridoxal-phosphate naphthylazo-nitro-disulfate (PPNDS) is actually an agonist, producing the same responses as beta,gamma-methylene ATP. [(32)P]ATP binding assays suggest that both agonists may bind to the same site as [(32)P]ATP. Cross-adaptation is also seen between PPNDS and beta,gamma-methylene ATP in terms of losses in AR, depolarizing receptor potentials and [(32)P]ATP binding. We conclude that the inhibition caused by PPNDS in Paramecium is due to agonist-induced desensitization. Either this represents a unique new class of ATP receptors, in which PPNDS is an agonist instead of an antagonist, or PPNDS (and other drugs like it) may actually be an agonist in many other cell types in which prolonged exposure is necessary for inhibition.
Wood
Christopher R
CR
Dept of Biological Sciences, State University of NY at Buffalo, Buffalo, NY 14260, USA.
Hennessey
Todd M
TM
D000255:Adenosine Triphosphate / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D001667:Binding, Competitive; D002118:Calcium / Q000378:metabolism; D008564:Membrane Potentials / Q000187:drug effects; D010247:Paramecium / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D010761:Phosphorus Radioisotopes; D058910:Purinergic P2 Receptor Agonists; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives* / Q000494:pharmacology*; D018048:Receptors, Purinergic P2 / Q000378:metabolism; D013451:Sulfonic Acids / Q000494:pharmacology*; D013550:Swimming / Q000502:physiology
D010761:Phosphorus Radioisotopes; D058910:Purinergic P2 Receptor Agonists; D018048:Receptors, Purinergic P2; D013451:Sulfonic Acids; C405633:pyridoxal-5'-phosphate-6-(2'-naphthylazo-6'-nitro-4',8'-disulfonate); C005147:5'-adenylyl (beta,gamma-methylene)diphosphonate; D011732:Pyridoxal Phosphate; D000255:Adenosine Triphosphate; D002118:Calcium